Cargando…

Feasibility of intraoperative detection of sentinel lymph nodes with 89-zirconium-labelled nanocolloidal albumin PET-CT and a handheld high-energy gamma probe

BACKGROUND: PET/CT lymphoscintigraphy using (89)Zr-nanocolloidal albumin has the potential to improve the preoperative identification of sentinel lymph nodes (SLNs), especially if located in the near proximity of the primary tumour. This study aims to demonstrate the feasibility of PET/CT lymphoscin...

Descripción completa

Detalles Bibliográficos
Autores principales: Heuveling, Derrek A., Karagozoglu, K. Hakki, Van Lingen, Arthur, Hoekstra, Otto S., Van Dongen, Guus A. M. S., De Bree, Remco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812956/
https://www.ncbi.nlm.nih.gov/pubmed/29445878
http://dx.doi.org/10.1186/s13550-018-0368-6
Descripción
Sumario:BACKGROUND: PET/CT lymphoscintigraphy using (89)Zr-nanocolloidal albumin has the potential to improve the preoperative identification of sentinel lymph nodes (SLNs), especially if located in the near proximity of the primary tumour. This study aims to demonstrate the feasibility of PET/CT lymphoscintigraphy followed by intraoperative detection of (89)Zr-nanocolloidal albumin containing SLNs with the use of a handheld high-energy gamma probe. METHODS: PET/CT lymphoscintigraphy was performed after peritumoural injection of (89)Zr-nanocolloidal albumin in five patients with oral cavity carcinoma planned for surgical resection. SLN biopsy procedure was performed 18 h later. SLNs were detected using detailed information of PET/CT and the high-energy gamma probe. RESULTS: In all patients, SLNs were identified on PET/CT lymphoscintigraphy. Intraoperative detection using the high-energy gamma probe was possible in 10 of 13 SLNs, at a short distance from the SLN. CONCLUSIONS: This study demonstrates that intraoperative detection of SLNs containing (89)Zr-nanocolloidal albumin using a handheld high-energy gamma probe is feasible, but its clinical use and sensitivity seem to be limited. TRIAL REGISTRATION: CCMO NL37222.092.11